{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:31:20Z","timestamp":1786995080804,"version":"build-2736575974"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:00:00Z","timestamp":1759449600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009882","name":"Regione Lombardia","doi-asserted-by":"publisher","award":["13.01.104.8378 2023"],"award-info":[{"award-number":["13.01.104.8378 2023"]}],"id":[{"id":"10.13039\/501100009882","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012352","name":"Universit\u00e0 degli Studi di Milano","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012352","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministry of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nutrition"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.nut.2025.112984","type":"journal-article","created":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T06:11:33Z","timestamp":1759558293000},"page":"112984","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Nutritional outcomes in people with cystic fibrosis receiving elexacaftor\/tezacaftor\/ivacaftor: A 24-mo real-world study"],"prefix":"10.1016","volume":"142","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0430-2714","authenticated-orcid":false,"given":"Gianfranco","family":"Alicandro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Zazzeron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1234-9765","authenticated-orcid":false,"given":"Valentina","family":"Visciola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Bulfamante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3786-2929","authenticated-orcid":false,"given":"Arianna","family":"Biffi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiola","family":"Corti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2315-5737","authenticated-orcid":false,"given":"Andrea","family":"Gramegna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Blasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Dacc\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nut.2025.112984_bib0001","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1016\/S0140-6736(16)00576-6","article-title":"Cystic fibrosis","volume":"388","author":"Elborn","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.nut.2025.112984_bib0002","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/path.4634","article-title":"Pancreatic pathophysiology in cystic fibrosis","volume":"238","author":"Gibson-Corley","year":"2016","journal-title":"J Pathol"},{"key":"10.1016\/j.nut.2025.112984_bib0003","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ccm.2015.11.004","article-title":"Gastrointestinal disorders in cystic fibrosis","volume":"37","author":"Assis","year":"2016","journal-title":"Clin Chest Med"},{"key":"10.1016\/j.nut.2025.112984_bib0004","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor\u2013tezacaftor\u2013ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nut.2025.112984_bib0005","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1164\/rccm.202102-0509OC","article-title":"A phase 3 open-label study of elexacaftor\/tezacaftor\/ivacaftor in children 6 through 11 years of age with cystic fibrosis and at least one F508del allele","volume":"203","author":"Zemanick","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.nut.2025.112984_bib0006","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jcf.2022.03.010","article-title":"Obesity in cystic fibrosis: prevalence, trends and associated factors data from the US cystic fibrosis foundation patient registry","volume":"21","author":"Szentpetery","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.nut.2025.112984_bib0007","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jcf.2024.11.009","article-title":"Cardiometabolic risk factors in adults with cystic fibrosis undergoing elexacaftor\/tezacaftor\/ivacaftor therapy","volume":"24","author":"Gramegna","year":"2025","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.nut.2025.112984_bib0008","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.jada.2008.02.020","article-title":"Evidence-based practice recommendations for nutrition-related management of children and adults with cystic fibrosis and pancreatic insufficiency: results of a systematic review","volume":"108","author":"Stallings","year":"2008","journal-title":"J Am Diet Assoc"},{"key":"10.1016\/j.nut.2025.112984_bib0009","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1016\/j.jcf.2022.01.010","article-title":"Hypervitaminosis A with fulminant secondary intracranial hypertension following personalized medicine-based elexacaftor\/tezacaftor\/ivacaftor initiation in a preadolescent with cystic fibrosis","volume":"21","author":"Wisniewski","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.nut.2025.112984_bib0010","doi-asserted-by":"crossref","DOI":"10.3390\/children10020252","article-title":"Nutritional status and circulating levels of fat-soluble vitamins in cystic fibrosis patients: a cohort study and evaluation of the effect of CFTR modulators","volume":"10","author":"Francalanci","year":"2023","journal-title":"Child"},{"key":"10.1016\/j.nut.2025.112984_bib0011","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1002\/ppul.25781","article-title":"Impact of elexacaftor\/tezacaftor\/ivacaftor on vitamin D absorption in cystic fibrosis patients","volume":"57","author":"Wright","year":"2022","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.nut.2025.112984_bib0012","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11236900","article-title":"Cystic fibrosis patients with F508del\/minimal function genotype: laboratory and nutritional evaluations after one year of elexacaftor\/tezacaftor\/ivacaftor treatment","volume":"11","author":"Carnovale","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.nut.2025.112984_bib0013","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.jcf.2023.04.019","article-title":"Impact of elexacaftor\/tezacaftor\/ivacaftor on fat-soluble vitamin levels in children with cystic fibrosis","volume":"22","author":"Schembri","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.nut.2025.112984_bib0014","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1002\/ppul.26823","article-title":"Impact of elexacaftor\/tezacaftor\/ivacaftor on lipid and fat-soluble vitamin levels and association with body mass index","volume":"59","author":"Patel","year":"2024","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.nut.2025.112984_bib0015","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.jcf.2023.08.002","article-title":"The impact of elexacaftor\/tezacaftor\/ivacaftor on fat-soluble vitamin levels in people with cystic fibrosis","volume":"22","author":"Hergenroeder","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.nut.2025.112984_bib0016","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/BF03344156","article-title":"Italian cross-sectional growth charts for height, weight and BMI (2 to 20 yr)","volume":"29","author":"Cacciari","year":"2006","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.nut.2025.112984_bib0017","unstructured":"World Health Organization. BMI-for-age (5\u201319 years). Growth Ref Data 5-19 Years 2016. https:\/\/www.who.int\/tools\/growth-reference-data-for-5to19-years\/indicators\/bmi-for-age (accessed August 28, 2025)."},{"key":"10.1016\/j.nut.2025.112984_bib0018","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.clnu.2023.12.017","article-title":"ESPEN-ESPGHAN-ECFS guideline on nutrition care for cystic fibrosis","volume":"43","author":"Wilschanski","year":"2024","journal-title":"Clin Nutr"},{"key":"10.1016\/j.nut.2025.112984_bib0019","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1515\/cclm-2016-0783","article-title":"Vitamin K plasma levels determination in human health","volume":"55","author":"Fusaro","year":"2017","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.nut.2025.112984_bib0020","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S2213-2600(21)00454-9","article-title":"Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial","volume":"10","author":"Sutharsan","year":"2022","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.nut.2025.112984_bib0021","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1164\/rccm.202102-0509OC","article-title":"A phase 3 open-label study of elexacaftor\/tezacaftor\/ivacaftor in children 6 through 11 years of age with cystic fibrosis and at least one F508del allele","volume":"203","author":"Zemanick","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.nut.2025.112984_bib0022","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02029-2022","article-title":"Long-term safety and efficacy of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis and at least one F508del allele: 144-week interim results from a 192-week open-label extension study","volume":"62","author":"Daines","year":"2023","journal-title":"Eur Respir J"},{"key":"10.1016\/j.nut.2025.112984_bib0023","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.jcf.2023.06.002","article-title":"Weight a minute: exploring the effect on weight and body composition after the initiation of elexacaftor\/tezacaftor\/ivacaftor in adults with CF","volume":"22","author":"Proud","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.nut.2025.112984_bib0024","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jcf.2004.04.003","article-title":"Vitamin A levels in patients with CF are influenced by the inflammatory response","volume":"3","author":"Greer","year":"2004","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.nut.2025.112984_bib0025","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.jcf.2024.02.005","article-title":"Vitamin D status and variable responses to supplements depend in part on genetic factors in adults with cystic fibrosis","volume":"23","author":"Braun","year":"2024","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.nut.2025.112984_bib0026","doi-asserted-by":"crossref","DOI":"10.1136\/jclinpath-2013-201787","article-title":"Fat-soluble vitamin deficiency in children and adolescents with cystic fibrosis","author":"Rana","year":"2014","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.nut.2025.112984_bib0027","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.jcf.2024.05.002","article-title":"Impact of extended elexacaftor\/tezacaftor\/ivacaftor therapy on the gut microbiome in cystic fibrosis","volume":"23","author":"Marsh","year":"2024","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.nut.2025.112984_bib0028","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/S0002-8223(21)00681-7","article-title":"Vitamin K and human nutrition","volume":"92","author":"Suttie","year":"1992","journal-title":"J Am Diet Assoc"},{"key":"10.1016\/j.nut.2025.112984_bib0029","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1016\/j.jcf.2022.01.010","article-title":"Hypervitaminosis A with fulminant secondary intracranial hypertension following personalized medicine-based elexacaftor\/tezacaftor\/ivacaftor initiation in a preadolescent with cystic fibrosis","volume":"21","author":"Wisniewski","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.nut.2025.112984_bib0030","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1016\/j.jcjo.2021.04.018","article-title":"Papilledema and hypervitaminosis A after elexacaftor\/tezacaftor\/ivacaftor for cystic fibrosis","volume":"57","author":"Miller","year":"2022","journal-title":"Can J Ophthalmol"},{"key":"10.1016\/j.nut.2025.112984_bib0031","doi-asserted-by":"crossref","DOI":"10.1002\/ppul.27455","article-title":"Pediatric pulmonology clinical correspondence papilledema in children with cystic fibrosis receiving elexacaftor\/tezacaftor\/ivacaftor: a multicenter case series","volume":"60","author":"Kam","year":"2025","journal-title":"Pediatr Pulmonol"},{"issue":"1","key":"10.1016\/j.nut.2025.112984_bib0032","doi-asserted-by":"crossref","first-page":"7719","DOI":"10.1038\/s41598-021-87099-w","article-title":"Vitamin D intoxication in patients with cystic fibrosis: report of a single-center cohort","volume":"11","author":"Plant\u00e9-Bordeneuve","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.nut.2025.112984_bib0033","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.2147\/PPA.S211769","article-title":"Adherence to long-term therapies in cystic fibrosis: a French cross-sectional study linking prescribing, dispensing, and hospitalization data","volume":"13","author":"Rouz\u00e9","year":"2019","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.nut.2025.112984_bib0034","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1080\/17476348.2017.1280399","article-title":"Adherence to therapies in cystic fibrosis: a targeted literature review","volume":"11","author":"Narayanan","year":"2017","journal-title":"Expert Rev Respir Med"},{"key":"10.1016\/j.nut.2025.112984_bib0035","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jcf.2024.05.007","article-title":"Standards for the care of people with cystic fibrosis (CF); planning for a longer life","volume":"23","author":"Gramegna","year":"2024","journal-title":"J Cyst Fibros"}],"container-title":["Nutrition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0899900725003028?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0899900725003028?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:44:30Z","timestamp":1778546670000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0899900725003028"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":35,"alternative-id":["S0899900725003028"],"URL":"https:\/\/doi.org\/10.1016\/j.nut.2025.112984","relation":{},"ISSN":["0899-9007"],"issn-type":[{"value":"0899-9007","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nutritional outcomes in people with cystic fibrosis receiving elexacaftor\/tezacaftor\/ivacaftor: A 24-mo real-world study","name":"articletitle","label":"Article Title"},{"value":"Nutrition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nut.2025.112984","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"112984"}}